Guest EM, Kairalla JA, Devidas M, Hibbitts E, Carroll AJ, Heerema NA, Kubaney HR, August MA, Ramesh S, Yoo B, Farooqi MS, Pauly MG, Wechsler DS, Miles RR, Reid JM, Kihei CD, Gore L, Raetz EA, Hunger SP, Loh ML, Brown PA. Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed <i>KMT2A</i&gt;-rearranged acute lymphoblastic leukemia: Children’s Oncology Group trial AALL15P1. Haematologica; https://doi.org/10.3324/haematol.2024.285158 [Early view].